Clinical trials
Thyroid Cancer, Papillary trials in China
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
40 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2015 | 3 |
| 2016 | 3 |
| 2017 | 1 |
| 2018 | 2 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 2 |
| 2022 | 5 |
| 2023 | 4 |
| 2024 | 10 |
| 2025 | 5 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Recruiting | 14 |
| Completed | 10 |
| Unknown status | 10 |
| Not yet recruiting | 4 |
| Active, not recruiting | 2 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 6 |
| Fujian Medical University | 4 |
| Chinese PLA General Hospital | 3 |
| Hoffmann-La Roche | 3 |
| Second Affiliated Hospital of Xi'an Jiaotong University | 3 |
| West China Hospital | 3 |
| Ming-an Yu | 2 |
| Nanfang Hospital, Southern Medical University | 2 |
| Sun Yat-sen University | 2 |
| Beijing Friendship Hospital | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Thyroid Cancer, Papillary | 40 |
| Thyroid Neoplasms | 9 |
| Lymphatic Metastasis | 6 |
| Thyroid Diseases | 3 |
| Anxiety Disorders | 2 |
| Brain Neoplasms | 2 |
| Carcinoma, Non-Small-Cell Lung | 2 |
| Colorectal Neoplasms | 2 |
| Head and Neck Neoplasms | 2 |
| Neuroendocrine Tumors | 2 |
Trials
Showing 26 to 40 of 40. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.